Skip to main navigation
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Press Releases

Jul 05, 2022
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
Jul 01, 2022
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
May 13, 2022
Adagio Therapeutics Reports First Quarter 2022 Financial Results
Apr 14, 2022
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
Mar 30, 2022
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization
Mar 18, 2022
Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
Feb 23, 2022
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
Feb 22, 2022
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
Feb 18, 2022
Adagio Therapeutics Announces CEO Succession Plan
Jan 12, 2022
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 11

For general inquiries:
info@adagiotx.com

For medical information
inquiries:
medinfo@adagiotx.com

781-819-0080

  • Follow
  • Follow

1601 Trapelo Road
Suite 178
Waltham, MA
02451

Privacy Policy   |   Terms of Use   |   Cookie Policy